‘No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia’: authors' response

Acta Psychiatrica Scandinavica

Volumn 136, Issue 5, 2017, Pages 526-527

  Ebdrup, B H ^a   Ishoy P L ^a   Fagerlund, B ^a,b   Broberg, B V ^a   Bak, N ^a   Knop, F K ^a,b   Glenthoj B Y ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NEUROLEPTIC AGENT;

BEHAVIOR CHANGE; CLINICAL PROTOCOL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; EARLY INTERVENTION; EVIDENCE BASED PRACTICE; HUMAN; LETTER; MENTAL DISEASE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; OBESITY; SCHIZOPHRENIA;

EID: 85028568835     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12795     Document Type: Letter

References (4)

1. Ishøy PL, Fagerlund B, Broberg BV et al. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr Scand 2017;136:52–62.
2. Ishøy PL, Fagerlund B, Broberg BV et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:162–171.
3. Ishøy PL, Knop FK, Broberg BV et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open 2014;4:e004158.
4. Knight J. Negative results: null and void. Nature 2003;422:554–555.